Top News rankings and signal summaries are processed using AI and may contain errors.
Cencora Inc. reported robust fourth-quarter financial results, with revenue rising 5.5% year-over-year to $88.4 billion and adjusted diluted earnings per share increasing 21.4% to $4.66. The company also declared a quarterly dividend increase to $0.66 per share, signaling confidence in its cash flow generation capabilities...
Cencora Inc. has agreed to acquire American Oncology Network for an enterprise value of USD 2.4 billion, marking a significant expansion in its oncology portfolio. The deal structure includes USD 2.3 billion in cash at closing and contingent value rights of up to USD 100...
Cencora Inc. reported robust fiscal fourth-quarter and full-year results, signaling strong earnings momentum as it enters fiscal 2027. Fourth-quarter revenue increased 5.5% year-over-year to $88.4 billion, while adjusted diluted EPS surged 21.4% to $4.66. For the full fiscal year ended September 30, 2026, revenue grew...
Argus Capital raised its price target for Cencora Inc. (COR) from USD 340.00 to USD 380.00 on October 20, 2026, signaling increased analyst confidence in the company's valuation and growth prospects. This bullish adjustment comes amidst a period of significant strategic expansion and strong financial...
Cencora, Inc. (NYSE: COR) announced a definitive agreement to acquire American Oncology Network (AON), a physician-led network comprising over 350 oncology providers across 21 states. The deal aims to expand Cencora's Managed Services Organization (MSO) platform and strengthen its presence in twelve additional states, thereby...
Baird Capital raised its price target for Cencora Inc. (COR) from USD 370.00 to USD 373.00 on October 12, 2026, maintaining an Outperform rating. The analyst firm cited the company's strong fiscal third-quarter performance as a key driver for the valuation adjustment, providing fresh upside...
Cencora (COR) reported a robust fiscal third quarter for 2026, delivering adjusted diluted earnings per share of $4.48, a 12.0% year-over-year increase, and revenue of $84.75 billion, up 5.1%. This performance marks the fifth consecutive quarter where the company exceeded consensus EPS estimates, driven significantly...
Cencora Inc. reported strong fiscal fourth-quarter results on November 4, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% year-over-year to $4.66. The company also posted GAAP EPS of $2.71, a significant turnaround from a loss in the...
Cencora, Inc. (COR) has announced a definitive agreement to acquire American Oncology Network (AON), a physician-led network comprising over 350 oncology providers located across 21 states. This strategic move is designed to significantly expand Cencora's existing oncology management services organization (MSO) platform, reinforcing its position...
Cencora, Inc. (formerly AmerisourceBergen) and its subsidiary The Lash Group have reached a definitive resolution regarding a massive data security incident that exposed the personal and protected health information of over 1.43 million individuals. Following months of litigation and administrative processing, a $40 million settlement...
Cencora (NYSE:COR) reported strong fiscal second-quarter results with adjusted diluted earnings per share rising 7.5% to $4.75, driven by higher operating income and robust revenue performance across its segments. Management raised its full-year adjusted EPS outlook while lowering full-year revenue growth expectations, attributing the latter...
Law Offices of Howard G. Smith has announced an ongoing securities fraud investigation targeting investors in Cencora, Inc. (NYSE: COR). The firm is seeking to represent shareholders who may have suffered financial losses due to alleged violations of federal securities laws and is inviting potential...
Cencora Inc. reported strong fourth-quarter results for the period ended September 30, 2026, with revenue rising 5.5% to $88.4 billion and adjusted diluted earnings per share increasing 21.4% to $4.66. The company also posted full-year fiscal figures showing a 5.0% revenue increase to $337.4 billion...
Cencora Inc. reported a strong fiscal third quarter in 2026, with adjusted earnings per share of USD 4.48 beating the consensus estimate of USD 4.37 by 2.52%. The company also posted GAAP earnings per share of USD 3.94 and total revenue of USD 84.75 billion,...
Cencora Inc. (COR) shares gained value after the company raised its full-year adjusted earnings per share (EPS) guidance to a range of USD 17.75 to 17.95, effective August 5, 2026. This upward revision follows strong fiscal third-quarter 2026 results where revenue grew 5.1% year-over-year to...
Cencora Inc. (COR) shares gained momentum following the release of solid fiscal 2026 results, driven by robust demand in specialty pharmaceuticals and updated full-year guidance. The company reported second-quarter revenue of USD 84.75 billion, marking a 5.1% year-over-year increase as it capitalized on growing demand...
Cencora Inc. shares gained value following the company's announcement of raised fiscal 2026 guidance and robust third-quarter earnings results. The stock traded near its recent high as investors reacted positively to year-on-year revenue growth and higher earnings per share reported for Q3 2026, which support...
Cencora Inc. shares gained value following the release of strong third-quarter fiscal 2026 earnings and a subsequent raise in full-year guidance for the same period. The company reported year-over-year revenue growth and increased earnings per share, driven by robust momentum within its core pharmaceuticals distribution...
Cencora (COR) reported quarterly earnings of $4.66 per share, surpassing the consensus estimate of $4.56 and representing a 2.19% surprise. This figure compares favorably to the prior year's adjusted earnings of $3.84 per share. The company has exceeded EPS estimates in three of its last...
Cencora Inc. has agreed to acquire American Oncology Network (AON) in a transaction valued at approximately USD 2.40 billion. The deal, announced on October 21, 2026, involves Cencora purchasing the equity interests in AON that it does not already own, as the company currently holds...